Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

NICV19 Antibodies: The Next Big Thing?

Mungiuby was the first second-line agent to get approved for diffuse large B cell lymphoma. The drug that they got approved, they got partnered with Insight and it gets approved in August 2020. But by then, what looked like kind of open spaces where they were going to have a ton of patients coming on this drug has become a knife fight. They sell all of these 28 programs I told you about, and including J&J's,. like, awesome blockbuster drug they've got, they sell it all to a company called Royalty Pharma  for $1.4 billion upfront.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner